Plasmablastic Lymphoma: A Systematic Review

Castillo, Jorge J.; Reagan, John L.

doi:10.1100/tsw.2011.59

Cited by 138 publications

(172 citation statements)

References 55 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…(3) PBL has a high incidence in HIV-positive patients and is more common in men. (2) PBL also seems to be more common in patients who have weakened immune systems due to infection by EBV or human herpes virus 8. Castillo et al, (4) who described the greatest number of PBL cases (n = 228), reported that 69% of patients (mean age = 39 years) were HIV-positive, and that most HIV-negative patients (mean age = 58 years) were EBV-positive.…”

Section: A S E R E P O R Tmentioning

confidence: 99%

“…Extranodal lymphoid organs, the central nervous system, peripheral lymph nodes, paranasal sinuses, mediastinum, lung, liver, and bone marrow may also be involved. (2) There have been recent reports of PBL in HIVnegative patients in whom the lesions mostly occurred in the extranodal tissues, including the skin, soft tissue, maxillary sinus, and gastrointestinal tract. There has been only one previous report of a simple breast PBL lesion.…”

Section: A S E R E P O R Tmentioning

confidence: 99%

“…(1,2) The World Health Organization (WHO) classifies PBL into the same subtype as HIV-related non-Hodgkin lymphoma (NHL). (3) PBL is characterised by the presence of B lymphocytes that are terminally differentiated and have a unique immunophenotype, with expressions of VS38c, CD38, MUM1 (multiple myeloma oncogene 1) and CD138, but minimal or no expressions of CD45, CD20, CD79a and PAX5.…”

Section: Introductionmentioning

confidence: 99%

“…(3) PBL is characterised by the presence of B lymphocytes that are terminally differentiated and have a unique immunophenotype, with expressions of VS38c, CD38, MUM1 (multiple myeloma oncogene 1) and CD138, but minimal or no expressions of CD45, CD20, CD79a and PAX5. (2) The diagnosis and treatment are challenging and the prognosis is often poor. (1,2) We herein report the diagnosis of a patient with PBL, who had a large breast mass and multiple organ involvement.…”

Section: Introductionmentioning

confidence: 99%

“…(2) The diagnosis and treatment are challenging and the prognosis is often poor. (1,2) We herein report the diagnosis of a patient with PBL, who had a large breast mass and multiple organ involvement. She was rapidly and successfully treated with chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of plasmablastic lymphoma with multiple organ involvement

Liang

Wang²,

Chen³

et al. 2014

smedj

View full text Add to dashboard Cite

Section: A S E R E P O R Tmentioning

confidence: 99%

Section: A S E R E P O R Tmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of plasmablastic lymphoma with multiple organ involvement

Liang

Wang²,

Chen³

et al. 2014

smedj

View full text Add to dashboard Cite

Human immunodeficiency virus‐associated plasmablastic lymphoma

Castillo

Furman

Beltrán

et al. 2012

Cancer

Self Cite

146

View full text Add to dashboard Cite

BACKGROUND: Plasmablastic lymphoma (PBL) is a rare and aggressive B‐cell lymphoma strongly associated with human immunodeficiency virus (HIV) infection. The authors conducted a multi‐institutional, retrospective study to describe characteristics and determine prognostic factors in HIV‐associated PBL. METHODS: For this study, the investigators included consecutive, HIV‐positive patients diagnosed between the years 2000 and 2010 whose tumors had a plasmablastic morphology, were cluster of differentiation 20 (CD20)‐negative, and expressed markers of plasmacytic differentiation. RESULTS: Fifty patients from 13 institutions were evaluated. The median age was 43 years, and there was a male predominance. The median count of cells that were positive for CD4 (a glycoprotein expressed on the surface of T‐helper cells, monocytes, macrophages, and dendritic cells) was 206 cells/mm3. At presentation, 90% of patients had extranodal involvement, 69% presented with advanced stage disease, and 27% had oral involvement. Rearrangements of v‐myc myelocytomatosis viral oncogene homolog (MYC) were detected in 41% of the tested patients. Eighty‐five percent of patients received chemotherapy, with 63% receiving cyclophosphamide, doxorubicin, vincristine, and prednisone and 37% receiving more intensive regimens. The complete response (CR) rate was 66%. The median overall survival (OS) was 11 months regardless of the intensity of chemotherapy. In the survival analysis, an Eastern Cooperative Oncology Group performance status ≥2, advanced stage, and MYC rearrangements were associated significantly with a worse outcome, whereas attaining a CR with chemotherapy was associated with a better outcome. CONCLUSIONS: The prognosis of PBL in HIV‐infected individuals remains poor in the highly active antiretroviral therapy era. Intensive chemotherapy regimens do not seem to increase survival in patients with HIV‐associated PBL. Cancer 2012. © 2012 American Cancer Society.

show abstract

Epstein‐Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018

Mpunga

Clifford

Morgan

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Few data exist on Epstein-Barr virus (EBV) prevalence across the full spectrum of lymphoma subtypes, particularly in sub-Saharan Africa. The objective of our study was to test the presence of EBV in a nationally representative sample of malignant lymphomas diagnosed in the Butaro Cancer Center of Excellence (BCCOE) in Rwanda. Of 102 Hodgkin (HL) and 378 non-Hodgkin lymphomas (NHL) diagnosed in BCCOE between 2012 and 2018, 52 HL and 207 NHL were successfully tested by EBV-encoding RNA in situ hybridization. EBV prevalence was 54% in HL, being detected in all classical HL subtypes: mixed-cellularity (n = 3/8), nodular-sclerosis (n = 7/17) and lymphocyte-rich (n = 2/3). EBV prevalence was 9% in NHL, being 10% among 158 B-cell NHL, 3% among 35 T-cellNHL and the single NK-cell NHL was EBV-positive. Among B-cell NHL, EBV was present in the majority of Burkitt (n = 8/13), and was also rarely detected in follicular (n = 1/4) and acute B-cell lymphoblastic (n = 1/45) lymphomas. Five of the 45 (11%) diffuse large B-cell lymphomas (DLBCLs) were EBV-positive, including three out of five plasmablastic lymphoma (PBL). Of 39 HL and 163 NHL of known human immunodeficiency virus (HIV) status, 2 (5%) and 14 (9%) were HIV-positive, respectively, of which only four were also EBVpositive (2 PBL, 2 HL). In summary, we report rare regional-level data on the association of EBV with classical HL, Burkitt and DLBCLs, and report sporadic detection in other subtypes possibly related to EBV. Such data inform the burden of disease caused by EBV and can help guide application of future advances in EBV-specific prevention and therapeutics.

show abstract

Plasmablastic Lymphoma: A Systematic Review

Cited by 138 publications

References 55 publications

Treatment of plasmablastic lymphoma with multiple organ involvement

Treatment of plasmablastic lymphoma with multiple organ involvement

Human immunodeficiency virus‐associated plasmablastic lymphoma

Epstein‐Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018

Contact Info

Product

Resources

About